Therapeutic Resistance and High-Risk Subsets in Advanced Melanoma

During a visit to Columbia University’s Herbert Irving Comprehensive Cancer Center, Targeted Oncology spoke with Benjamin Izar, MD, PhD, about treatment resistance as a primary and persistent challenge in the field of advanced melanoma. It affects patients receiving both immunotherapy and targeted therapies, such as BRAF/MEK inhibitors. Despite significant research efforts, the full spectrum of resistance mechanisms remains incompletely understood. Izar emphasized that this is a highly active area of investigation at institutions like his, where researchers aim to decode these mechanisms to develop more rationally designed, specific therapies.

Beyond general resistance, Izar highlighted 2 specific patient subsets that face particularly poor outcomes.

Brain metastases are a frequent complication in melanoma that often leads to high morbidity and mortality due to the limited space within the skull and the sensitivity of the organ. While systemic therapies can be effective, the brain often serves as a "sanctuary site" where the disease responds less robustly or recurs more quickly than in other parts of the body.

The presence of large liver metastases is one of the strongest negative predictors for both overall prognosis and treatment response across various cancer types. Specifically, immunotherapies tend to be less effective in patients with liver involvement.

Izar noted that understanding why liver metastases diminish systemic treatment efficacy requires viewing cancer as a whole-body, systemic disease. The presence of cancer in the liver appears to alter the entire organism's physiology, rendering patients less likely to respond to therapy. Research continues into these systemic alterations to improve the clinical outlook for these high-risk phenotypes.